Activation of EZH2 Promoter Is Mediated by MAPK Signaling Regulated Transcription Factors in Anaplastic Thyroid Cancer
International Journal of Molecular Sciences · 18.07.2026 · 27 (14) · 6402
DOI: 10.3390/ijms27146402 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 18.07.2026. Verfasst von Marcella Maringolo Cristovão und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell and Developmental Biology, Institute of Biomedical Sciences, University of São Paulo (USP), São Paulo 05508-000, SP, Brazil. Hauptthemen laut MEDLINE: Thyroid Carcinoma, Anaplastic, Enhancer of Zeste Homolog 2 Protein, Promoter Regions, Genetic, Thyroid Neoplasms. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo, Conselho Nacional de Desenvolvimento Científico e Tecnológico, Sao Paulo Research Foundation—FAPESP.
Abstract (Originalsprache)
Anaplastic thyroid carcinoma (ATC) is the most aggressive thyroid cancer type harboring TP53, TERT promoter and MAPK signaling alterations. Additionally, EZH2 overexpression leads to epigenetic silencing of tumor suppressor and cell differentiation genes. Here, we investigate the mechanism of EZH2 transcriptional activation in ATC. We used several luciferase reporter constructs with deletion of transcription factor (TF) binding sites identified in silico to determine EZH2 minimal promoter in ATC. MAPK signaling blockage with U0126, TF overexpression and knock-down strategies were used to evaluate EZH2 expression and reporter plasmid response, and the cross talk with TFs. As a result, we observed that EZH2 transcription is regulated by a minimal promoter of 107 bp (E3/4 region), that contains binding sites for TF NFYA, YY1 and FOXM1, highly expressed in ATC, that when deleted reduced EZH2 promoter activation. MAPK blockage reduced EZH2 and influenced YY1 and FOXM1 TF levels, while overexpression of NFYA, YY1 and FOXM1 resulted in pro-tumoral effects and EZH2 upregulation in papillary thyroid cancer cells. On the other hand, FOXM1 knock-down reduced EZH2 activation in ATC cells. Thus, we identified the minimal promoter region essential for EZH2 activation in ATC that is controlled by MAPK signaling in crosstalk with TFs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cell and Developmental Biology, Institute of Biomedical Sciences, University of São Paulo (USP), São Paulo 05508-000, SP, Brazil.
- Department of Biochemistry, Escola Paulista de Medicina, Universidade Federal de São Paulo (UNIFESP), São Paulo 04044-020, SP, Brazil.
ORCID-Profile: Marcella Maringolo Cristovão, Diego Claro de Mello, Edna Teruko Kimura, Cesar Seigi Fuziwara
Förderung
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Sao Paulo Research Foundation—FAPESP
- National Council for Scientific and Technological Development—CNPq
Zitieren
APA
Cristovão, M. M., de Mello, D. C., Kimura, E. T., & Fuziwara, C. S. (2026). Activation of EZH2 Promoter Is Mediated by MAPK Signaling Regulated Transcription Factors in Anaplastic Thyroid Cancer. International Journal of Molecular Sciences, 27(14), 6402. https://doi.org/10.3390/ijms27146402
Vancouver
Cristovão MM, de Mello DC, Kimura ET, Fuziwara CS. Activation of EZH2 Promoter Is Mediated by MAPK Signaling Regulated Transcription Factors in Anaplastic Thyroid Cancer. International Journal of Molecular Sciences. 2026;27(14):6402. doi:10.3390/ijms27146402
BibTeX
@article{Cristovo2026,
author = {Cristovão, Marcella Maringolo and de Mello, Diego Claro and Kimura, Edna Teruko and Fuziwara, Cesar Seigi},
title = {Activation of EZH2 Promoter Is Mediated by MAPK Signaling Regulated Transcription Factors in Anaplastic Thyroid Cancer},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {14},
pages = {6402},
doi = {10.3390/ijms27146402}
}
EUVIMED